#1
#1 out of 1
business1d ago
Jim Cramer on Amgen: “They Have A Lot of Good Medicines”
- Cramer urged Amgen to broaden its portfolio and tell a clearer story about its medicines.
- Cramer noted Amgen’s quarterly results were strong but the market reacted negatively.
- The discussion references Amgen’s product lines, including Enbrel, Prolia, and Repatha.
- Cramer compared Amgen’s MariTide to other therapies, noting dosing differences.
- The article ties Amgen’s potential to broader AI stock opportunities and market trends.
- The piece cites a June 25 episode as the moment Cramer discussed Amgen.
- Market data shown includes major indices and Amgen-related movers.
- The article identifies Amgen’s stock ticker AMGN and segments of the company’s business.
- Cramer’s commentary aimed at shaping investor perception of Amgen’s future.
- The piece mentions general background on Amgen’s industry context and pipeline relevance.
Vote 0